08.11.2005 – 10:04

november AG

euro adhoc: november AG
Financial Figures/Balance Sheet
november AG with positive quarter and nine months’ statement on group level Third quarter with improved consolidated and operating result

  Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.

08.11.2005

Erlangen, 08 November 2005. november AG, the development and holding
company (ISIN DE0006762909) located in Erlangen, improved its
consolidated operating result (EBIT) to -1.616 million EUR by 48% in
the first nine months of 2005 compared to previous years reporting
period. Thus november AG specialised in bio- and nanotechnology
continues the positive trend of the last quarters. On group level
revenues increased up to 4.86 million EUR being 28% higher than the
last year’s figure (3.8 million EUR). Due to intensified marketing
and distribution activities sales and marketing expenses increased to
1.83 million EUR (prior year’s reporting period 1.72 million EUR)
according to plan. Research and development expenses rose by 7% to
2.27 million EUR as forecasted. The general and administrative
expenses could be reduced by 6% to 1.2 million EUR. At the end of the
first nine months november AG’s total liquidity was 5.52 million EUR.
Total assets on group level amounted to 26.32 million EUR at the end
of the third quarter (31.12.04: 27.68 million EUR). Earnings per
share (EPS) improved significantly from EUR   -0.26 for the first
nine months of 2004 up to EUR  -0.11.  The fully consolidated
companies of the november Group engaged from 01.01.2005 to 30.09.2005
on average 61 full time employees.

Annotations  november AG is an Erlangen (Germany) based listed
biotech company (Frankfurt Stock Exchange Prime Standard, ISIN
DE0006762909, SE symbol NBX) with, inter alia, a focus on development
in the field of nanotechnology. Organized as a holding company, the
group also includes the subsidiaries identif GmbH (product security &
brand protection), directif GmbH (lab independent nucleic acid
testing), and PEQLAB Biotechnologie GmbH (biotech R&D supplier).
Since 2002, first brand protection products are available with pharma
company Bristol-Myers Squibb (Germany) among the first customers. For
diagnostics and based on a patented technology, directif GmbH
develops the world's first fully integrated nucleic acid testing
device which will provide fast and cost-efficient detection of
pathogens on the genetic level even at the point of care. On a
contractual basis, november will participate in the development of a
novel immunotherapeutic approach to fight cancer through profit share
options. This new therapy is being developed by responsif GmbH, the
former therapeutic business unit of november AG whose management
conducted a management buy-out in early 2003.

end of announcement                               euro adhoc 08.11.2005 09:24:57

Further inquiry note:

Marcus Weichert
november AG - Public Relations/Investor Relations
Ulrich-Schalk-Str. 3, D-91056 Erlangen
Tel.: +49 (0)9131 750 88 868
e-mail: weichert@november.de, www.november.de

Branche: Biotechnology
ISIN: DE0006762909
WKN: 676290
Index: CDAX, Technologie All Share, Prime All Share, Prime Standard
Börsen: Frankfurter Wertpapierbörse / regulated dealing
Berliner Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Niedersächsische Börse zu Hannover / free trade
Bayerische Börse / free trade
Bremer Wertpapierbörse (BWB) / free trade